ASX BRIEFS

EPIMINDER LTD (ASX:EPI) - A New Standard For Epilepsy Monitoring

• Andrew Musgrave

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 6:33

Send us Fan Mail

ASX Investment Opportunity - Epiminder Ltd (ASX:EPI)

Seizure diaries ask people to remember the hardest moments of their lives, then clinicians are expected to make high-stakes treatment calls off that memory. That’s the gap Epiminder Limited wants to close, and we’re joined by CEO Rohan Hoare to explain how continuous long-term EEG monitoring could push epilepsy care towards objective evidence rather than best guesses. 

Rohan breaks down what Epiminder actually builds: an implantable EEG device placed under the scalp, paired with a wearable, a companion phone, and a cloud app. We talk about why long-duration brain activity monitoring across months to years can reveal patterns that short clinical snapshots miss, and why that matters for drug-resistant epilepsy. He also shares a striking data point from Australian work used for FDA authorisation, where EEG monitoring informed clinical decision making 88% of the time, a reminder that better data can directly shape better care. 

We then dig into execution and timelines: the US DETECT post-market reimbursement trial has enrolled its 100th participant ahead of schedule across 23 centres, including leading institutions like Harvard, Stanford, Yale, UPenn, and Mayo. Rohan outlines the milestones to watch through 2026 and into 2027, the recent FDA clearance expanding the indicated age range to patients aged 12 and older, and how Epiminder’s strong cash position supports four priorities: completing DETECT, delivering a next-generation slimline device designed for manufacturability, proving early revenue across key segments (including US Medicare, the VA, pharma partners, and Australia’s SAS scheme), and building a go-to-market model aimed at a commercial launch around early 2028. 

If you care about epilepsy innovation, digital health, medical device commercialisation, or ASX healthcare stories, subscribe, share this with a mate, and leave a review. What part of objective seizure monitoring do you think will drive adoption first: clinicians, patients, or reimbursement?